These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21844308)

  • 1. Strengthening observational evidence for antiviral effectiveness in influenza A (H5N1).
    Adisasmito W; Chan PK; Lee N; Oner AF; Gasimov V; Zaman M; Bamgboye E; Dogan N; Starzyk K; Dreyer NA; Toovey S
    J Infect Dis; 2011 Sep; 204(5):810-1. PubMed ID: 21844308
    [No Abstract]   [Full Text] [Related]  

  • 2. Has oseltamivir been shown to be effective for treatment of H5N1 influenza?
    Couch RB; Davis BR
    J Infect Dis; 2010 Oct; 202(8):1149-51. PubMed ID: 20831386
    [No Abstract]   [Full Text] [Related]  

  • 3. H5N1 virus resistant to antiviral drug.
    Chen HL; Guan Y
    Hong Kong Med J; 2015 Jun; 21 Suppl 4():12-3. PubMed ID: 26157095
    [No Abstract]   [Full Text] [Related]  

  • 4. Assay to detect H5N1 oseltamivir resistance.
    Suwannakarn K; Chutinimitkul S; Payungporn S; Chieochansin T; Theamboonlers A; Amonsin A; Damrongwatanapokin S; Mai le Q; Hanh NH; Poovorawan Y
    Emerg Infect Dis; 2006 Dec; 12(12):1995-6. PubMed ID: 17354342
    [No Abstract]   [Full Text] [Related]  

  • 5. Foreword: Oseltamivir for seasonal, avian and pandemic influenza: 10 years of clinical experience.
    Nguyen-Van-Tam JS
    J Antimicrob Chemother; 2010 Apr; 65 Suppl 2(Suppl 2):ii3-ii4. PubMed ID: 20215133
    [No Abstract]   [Full Text] [Related]  

  • 6. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
    Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
    Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment options for H5N1: lessons learned from the H1N1 pandemic.
    Reece PA
    Postgrad Med; 2010 Sep; 122(5):134-41. PubMed ID: 20861597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry.
    Adisasmito W; Chan PK; Lee N; Oner AF; Gasimov V; Aghayev F; Zaman M; Bamgboye E; Dogan N; Coker R; Starzyk K; Dreyer NA; Toovey S
    J Infect Dis; 2010 Oct; 202(8):1154-60. PubMed ID: 20831384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tamiflu resistance].
    Nau JY
    Rev Med Suisse; 2006 Dec; 2(91):2886. PubMed ID: 17236332
    [No Abstract]   [Full Text] [Related]  

  • 10. [Bird flu: increased resistance to oseltamivir. Are our weapons already blunt? (interview by Dr. Elke Oberhofer)].
    Nothdurft HD
    MMW Fortschr Med; 2006 Oct; 148(41):22. PubMed ID: 17190255
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of a specific polyclonal equine F(ab')2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir.
    Herbreteau CH; Denizot M; Lowther S; Riddell S; Frazer L; Haining J; Arkinstall R; Payne J; Harper J; Johnson D; Pasquier A; Middleton D; Saluzzo JF
    Immunotherapy; 2016 Sep; 8(9):1021-32. PubMed ID: 27380317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of Tamiflu under pandemic conditions].
    Nau JY
    Rev Med Suisse; 2009 Jul; 5(211):1532. PubMed ID: 19694366
    [No Abstract]   [Full Text] [Related]  

  • 13. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model.
    Boltz DA; Rehg JE; McClaren J; Webster RG; Govorkova EA
    J Infect Dis; 2008 May; 197(9):1315-23. PubMed ID: 18422444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants?
    Rungrotmongkol T; Udommaneethanakit T; Malaisree M; Nunthaboot N; Intharathep P; Sompornpisut P; Hannongbua S
    Biophys Chem; 2009 Nov; 145(1):29-36. PubMed ID: 19733000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses.
    Paules CI; Lakdawala S; McAuliffe JM; Paskel M; Vogel L; Kallewaard NL; Zhu Q; Subbarao K
    J Infect Dis; 2017 Aug; 216(3):356-365. PubMed ID: 28633457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on avian influenza A (H5N1) virus infection in humans.
    ; Abdel-Ghafar AN; Chotpitayasunondh T; Gao Z; Hayden FG; Nguyen DH; de Jong MD; Naghdaliyev A; Peiris JS; Shindo N; Soeroso S; Uyeki TM
    N Engl J Med; 2008 Jan; 358(3):261-73. PubMed ID: 18199865
    [No Abstract]   [Full Text] [Related]  

  • 17. Possible case scenarios and logistic issues in H5N1 pandemic.
    Tsang KW; Shim YS; Wong TK; Liam CK; Eng P; Lam WK; Seto WH
    Respirology; 2006 Sep; 11(5):520-2. PubMed ID: 16916322
    [No Abstract]   [Full Text] [Related]  

  • 18. Interaction between oseltamivir and herbal medicines used for treating avian influenza.
    Yang MS; Law FC; Wong RN; Mak NK; Wei XY
    Hong Kong Med J; 2012 Dec; 18 Suppl 6():34-6. PubMed ID: 23249852
    [No Abstract]   [Full Text] [Related]  

  • 19. Probenecid with oseltamivir for human influenza A (H5N1) virus infection?
    Howton JC
    N Engl J Med; 2006 Feb; 354(8):879-80. PubMed ID: 16495407
    [No Abstract]   [Full Text] [Related]  

  • 20. ECDC public consultation on the use of neuraminidase inhibitors.
    Eurosurveillance editorial team
    Euro Surveill; 2016; 21(7):pii=30140. PubMed ID: 27358927
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.